Compare Abeona Therapeutics Inc (ABEO) vs Appian Corp (APPN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Appian Corp — how do they compare? Abeona Therapeutics Inc trades at $6.78 (market cap $373.32M), while Appian Corp trades at $24.23 (market cap $1.81B). The key difference: Appian Corp is far larger — about 4.8× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Appian Corp nearer its low. Which is the better fit depends on your goals.
| ABEO | APPN | |
|---|---|---|
Market Cap | $373.32M | $1.81B |
Sector | Health | Technology |
52-Week High | $7.23 | $45.64 |
52-Week Low | $4.17 | $18.72 |
Enterprise Value | $228.22M | $1.90B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Appian (APPN) trades at $24.68, up 1.15% with bullish technical signals from moving averages. The company shows strong revenue growth reaching $727M in 2025 and has beaten earnings estimates for three consecutive quarters. However, profitability remains minimal with a net margin of just 0.12% and negative shareholder equity of -$32.64M. Recent CEO stock sales and mixed analyst sentiment create uncertainty despite positive AI-driven business developments.
Appian presents a growth story with improving cash flow and AI positioning, but faces significant profitability challenges and negative equity. The stock trades near analyst consensus target of $26.20, suggesting limited upside. Key risks include sustained unprofitability and high debt levels, while opportunities lie in enterprise AI adoption and cloud revenue growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Appian Corp
Appian Corp provides a low-code software development platform as a service that enables organizations to rapidly develop powerful and unique applications. With its platform, organizations can rapidly and easily design, build and implement powerful, enterprise-grade custom applications through intuitive, visual interface with little or no coding required. The company's customers use applications built on its low-code platform to launch new business lines, automate vital employee workflows, manage complex trading platforms, accelerate drug development and build procurement systems. The group generates a majority of its revenue from the domestic market. It serves various industries such as education.
Read more on APPN →
